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Abstract 
It is no longer necessary to demonstrate that ribosome is the central machinery of protein 
synthesis. But it is less known that it is also key player of the protein folding process through 
another conserved function: the protein folding activity of the ribosome (PFAR). This ribozyme 
activity, discovered more than two decades ago, depends upon the domain V of the large rRNA 
 
 2 
within the large subunit of the ribosome. Surprisingly, we discovered that anti-prion compounds 
are also potent PFAR inhibitors, highlighting an unexpected link between PFAR and prion 
propagation. 
In this review, we discuss the ancestral origin of PFAR in the light of the ancient RNA world 
hypothesis. We also consider how this ribosomal activity fits into the landscape of cellular 
protein chaperones involved in the appearance and propagation of prions and other amyloids in 
mammals. Finally, we examine how drugs targeting the protein folding activity of the ribosome 
could be active against mammalian prion and other protein aggregation-based diseases, making 
PFAR a promising therapeutic target for various human protein misfolding diseases. 
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Present in every cell and mitochondria, ribosomes are composed of two subunits, which 
themselves are made up of ribosomal RNA (rRNA) and proteins. Broadly, the small subunit 
initiates the translational process and ensures the correct decoding of genetic information, while 
the large subunit catalyzes the peptidyl transferase activity that covalently links amino acids 
together. While the central role of the ribosome in protein synthesis is well appreciated, little is 
known about the second ribozyme activity of the ribosome: its protein folding activity (PFAR). 
Since its discovery, the existence of PFAR has been controversial and difficult to gain 
acceptance within the scientific community. Despite PFAR being first identified in 1994 by the 
group of C. Das Gupta 
1
 and this activity being corroborated by several other teams 
2
, PFAR is 
often overlooked, as illustrated by its absence from reviews on non-coding RNAs. However, 
once getting over the initial surprise of the existence of such an activity, it seems self-evident 
that the biological entity that has evolved to synthesize proteins must also aid them achieve a 
proper three-dimensional functional state prior to their release. In addition, this is fully consistent 
with the estimation that, apart from spontaneously folded proteins, only a fraction of the total 
cellular proteins can be folded by classical protein chaperones 
3
. 
Initially, PFAR was described in vitro for bacterial ribosomes and was quickly shown to be a 
conserved function of any ribosome, whether from bacteria, eubacteria, eukaryotes or even 
mitochondria 
2
. The conservation of the protein folding capacity of the ribosome among species 
is not a surprise when considering the high rate of conservation of rRNA in the ribosome core 
throughout evolution 
4
. As one may expect, PFAR is a versatile process that has been 
demonstrated to be able to refold any protein challenged so far in vitro 
2
 and in vivo 
5--8
. This 
folding activity appears to be inherent to the conserved RNA domain that also harbors the 
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peptidyl transferase activity: domain V of the rRNA of the large subunit of the ribosome (23S for 
bacteria, 25S for yeast and 28S for mammals). However, the nucleotides of domain V involved 
in its protein folding activity are different from those involved in its peptidyl transferase activity 
9, 10
 (Figure 1). 
The protein folding mediated by domain V is a two-step post-translational process: the neo-
synthesized polypeptide is firstly folded by the central loop of domain V (RNA1) and remains 
associated to it until the intervention of a second part of domain V (RNA2) which is responsible 
for the release of the folded protein 
11
. The nucleotides involved in PFAR are localized at the 
interface of the ribosome’s small and large subunits 
9
. Ribosomal subunits dissociate in the 
presence of unfolded polypeptides, making them more accessible to PFAR-involved nucleotides 
and thus enhancing their folding ability 
2
. This is in good agreement with the fact that protein 
synthesis and protein folding are synchronized: as long as the peptidyl transferase activity 
continues, the protein folding activity of the ribosome is silenced and only becomes operational 
when translation is completed 
12
. 
In the midst of identifying new anti-prion compounds, we identified anti-prion drugs such as 6-
aminophenanthridine (6AP, 
13
), guanabenz (GA, 
14
) and imiquimod (IQ, 
15
) which are active in 
vivo against yeast and mammalian prions and that were amazingly identified as PFAR inhibitors. 
The discovery that 6AP and GA anti-prion drugs are also anti-PFAR drugs led us naturally to 
suggest that PFAR may be linked to prion propagation. Although the primary role of protein 
chaperones is to prevent protein misfolding and aggregation, involvement of protein chaperones 
like PFAR in the propagation of prion conformation is self-evident, as amyloid-forming proteins 
exist in several conformations and replication corresponds to propagation of differentially folded 
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states 
16
. This hypothesis has strong support as Hsp104p, a yeast heat shock protein, has been 
shown for a long time to be involved in yeast prion propagation, together with Hsp70 and Hsp40. 
Similarly to Hsp104p, PFAR misregulation leads to a defect in the propagation of the yeast prion 
[PSI
+
] 
6
 (Figure 2). The anti-PFAR drugs we identified were the first of that kind: all the 
previous anti-PFAR drugs described so far are antibiotics that also bind to domain V and inhibit 
its peptidyl transferase activity 
5, 7
. Of note, the fact that some antibiotics specifically target 
PFAR is a further indication of the central function of this ribozyme activity. 
In this review, we consider the ancestral origin of PFAR and the relationship of this emerging 
ribosomal activity with the global protein folding capacity of the cell. We also discuss PFAR 
involvement in the propagation of prions and other amyloids in mammals. 
PFAR activity: another relic of the ancient RNA world into modern ribosomes? 
In current living organisms, the newly synthesized polypeptides undergo several maturation 
mechanisms in order to be correctly processed and translocated to achieve their functional folded 
state. These maturation processes are often linked to protein synthesis. They depend on 
translational speed and on interactions of the nascent polypeptide chain with the peptide exit 
tunnel and with the nascent chain-interacting protein factors, which are located on and around 
the ribosomal tunnel exit area. Beyond, a network of other cooperating chaperones acting post-
translationally in a coordinated ballet are also involved during the latter stages of the protein 
folding process 
17
. However, this system brings the endless chicken-and-egg paradox back into 
play: to get mature and functional proteins, the cell needs… mature and functional chaperoning 
factors! To address this paradox, one has to consider the evolution of the protein folding process 
and how the ancient foundations may have developed. In the ancient RNA world hypothesis, 
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earlier forms of life may rely on the dual function of RNA that simultaneously catalyzes 
enzymatic reactions and store genetic information 
18
. This suggests that RNA could be the main 
actor that carried out the chemical reactions allowing proteins to gradually emerge and become 
more complex due to the development of more and more sophisticated protein folding 
capabilities. Many molecular fossils of the ancient RNA world are still present and sometimes 
still active in modern organisms. Candidates must be catalytic, ubiquitous, and/or central to some 
aspect of metabolism 
19
. Accordingly, one of the most significant piece of evidence to support 
that the first peptide bonding machines emerged in an RNA world is the fact that the modern 
ribosome is a ribozyme, or in other words that only RNA performs its key role in peptide bond 
formation 
20
. The peptidyl-transferase center (PTC) of the modern ribosome is a universal and 
highly conserved RNA-only structure located in the domain V of 23S rRNA in bacteria or its 
equivalent parts in eukaryotic ribosome. It forms a symmetrical pocket in the heart of the large 
ribosomal subunit and probably originated from the dimerization of two stem–elbow–stem 
motifs 
21
. The PTC is considered to be the first proto-ribosome dating from the ancient RNA 
world since it was certainly capable of triggering catalytic reactions by itself. Strikingly, as 
supported by the binding sites of its protein substrates or inhibitors, PFAR activity is clustered 
within the PTC binding pocket, surrounding the core where the catalytic reaction takes place 
9, 22
 
(Figure 1). Therefore, PFAR encompasses most criteria for making it a perfect vestige of the 
ancient RNA world as it is: i) part of another ribozyme, the PTC, ii) as ancient as the PTC, iii) 
supported by RNA only, iv) conserved from bacteria to eukaryotes and v) capable of playing a 
key role in modern protein synthesis. In this scenario, the first PTCs (proto-PTCs) were formed 
by the dimerization of short helical structures that created the first random but fragile peptides 
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aleatory using amino acids. In a process that might be assimilated as “molecular Darwinism” 
23
, 
these proto-PTCs would then have evolved into a stable PTC, able to better favor protection, 
stability and activity of the peptides they synthesized. While one can assume that the earliest 
peptides were short, single domain and rapidly selected for robust chaperone-independent 
folding, the emergence of a primitive PFAR certainly conferred a selective advantage to the 
peptides. In turn, and resulting from the more and more efficient peptides and proteins being 
produced, the proto-PTC slowly co-evolved into a proto-ribosome and finally into the modern 
ribosome we recognize today, likely by progressively integrating multiple small 
ribonucleoprotein complexes into a much more complex machinery 
24
. The traces of these 
ancient times remain active RNAs such as domain V harboring PTC and PFAR, still embedded 
in contemporary ribosomes, and may continue to play a role as part of the global protein folding 
capability of the cell. 
Which place PFAR could take in the array of protein chaperones? 
Prion propagation in yeast has been shown to be intimately linked to the expression and activity 
of a plethora of protein chaperones. We recently showed that PFAR and Hsp104p partially 
compensate each other for [PSI
+
] propagation in yeast (Figure 2). We indeed observed that 
PFAR up-modulation can compensate for the partial loss of Hsp104p activity and that PFAR 
partial down-modulation is also compensated by Hsp104p increase 
6
. These results clearly 
indicate that PFAR is linked to the cellular array of protein chaperones, at least through 
Hsp104p. To this respect, PFAR participates to the very complex network required for cell 
proteostasis, i.e. the global protein quality control and the maintenance of proteome homeostasis. 
Of note, polynucleotides, and more particularly RNAs, have been shown to exhibit potent 
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chaperone activity in vitro 
25
. Proteostasis involves hundreds of proteins constituting a highly 
regulated and integrated network. 
One of the main challenges of the cellular response to stress is to synthesize, under adverse 
conditions, correctly folded proteins essential for survival. Since the PTC and PFAR are 
intimately linked, PFAR activity directly depends upon the synthesis of proteins, thus allowing 
the cell to establish a proper equilibrium between protein production and folding activities. In 
this context, the link between the PTC and PFAR can be seen as a strategy to avoid the synthesis 
of a polypeptide in the absence of efficient cellular folding activities. Remarkably, in situations 
of cellular stress, translation is strongly reduced, which consequently increases the population of 
non-translating ribosomes becoming available for protein folding. As a consequence, the 
corresponding misfolded proteins emerging from the deficient ribosome will be more prone to 
proteolysis. Thus, PFAR could also participate to proteostasis as a potential proofreading process 
of the PTC activity. 
While Hsp104, and now PFAR, are key players in dictating the appearance and propagation of 
naturally occurring amyloid-based yeast prions, members of the cytosolic Hsp70 chaperone 
machinery, and associated co-chaperones, are important modulators of prion propagation, and in 
some instances de novo prion formation 
16, 26
. The cytosolic Hsp70-Ssa [Stress Seventy Sub-
Family A] family members are well characterised as playing an integral role in modulating the 
propagation of a variety of yeast prions 
27, 28
 and the ribosome-associated Hsp70-Ssb [Stress 
Seventy Sub-Family B] family members are anti-prion in their action since they repress the 
spontaneous appearance of [PSI
+
] 
29
. Of note, contrary to Hsp104p and Hsp70 which expression 
is induced by stress, PFAR is a ready-to-use protein folding source immediately available in case 
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of heatshock to supplement Hsp104 or to compensate for its absence, similarly to mammals 
where there is no HSP104 homolog. 
Where could PFAR “sit” amongst these other cellular factors and how may they interact to 
influence prion propagation, or other protein folding events in vivo? One possibility is that some 
prion phenotypes consecutive to alterations in PFAR activity could result from indirect effects 
through alteration of chaperone systems such as the cytosolic Hsp70 machinery. However, such 
phenotypes are not due to indirect effects on Hsp70 abundance 
6
 and it is unlikely that alterations 
in PFAR activity could significantly disturb Hsp70 specific functions, unless through indirect 
effect on Hsp70 co-chaperone activities. PFAR could possibly work in conjunction or in tandem 
with Hsp70s or other chaperones and the association of Hsp70-Ssb and the interaction with RAC 
[Ribosome Associated Complex] in prion formation and propagation 
30
 provides the basis for 
such interactions to evolve. Chaperones often function as multi-complex machines and it is 
conceivable that Hsp70 or co-chaperones could be involved into the delivery or processing of 
substrates acted upon by PFAR, or that PFAR could process substrates acted on by downstream 
chaperone machinery. The construction and characterisation of yeast cells modified to alter 
PFAR activity now provides the basis for a thorough genetic assessment of interaction between 
PFAR and an array of protein chaperone pathways. The involvement of PFAR in protein 
homeostasis could extend well beyond prion propagation and should it be the case, the 
integration with other chaperone networks is even more likely. 
PFAR: mammalian prion propagation and beyond? 
How could drugs targeting the protein folding activity of the ribosome, which mainly lies in the 
cytoplasm, be active against mammalian prion PrP
Sc
, which is believed to be modified mostly at 
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the cell surface or on endocytic compartments? Addressing this question emphasizes our lack of 
precise knowledge regarding the cellular compartments where prion conversion and subsequent 
accumulation occur. This is partly due to the fact that direct and dynamic visualization in cells 
remains a highly challenging issue, notably because tagging the cellular form of the prion protein 
(PrP
C
) most often prevents its conversion into the disease-specific isoform PrP
Sc
. In many 
differentiated cell types, a major proportion of PrP
C
 is detected in lipid rafts at the cell surface, 
being anchored by a GPI moiety (for review 
31
). PrP
C
 expression at the cell surface is required 
for conversion into misfolded PrP
Sc
 
32, 33
 and this process may occur rapidly 
32
. Several reports 
also indicate that a substantial fraction of PrP
C
 cycles constitutively between the plasma 
membrane and endocytic compartments and that conversion can also occur in several 
intracellular compartments all along the endocytic pathway 
34--36
. A minor proportion of PrP
C
 can 
be found in the cytosol or in contact with the cytosol, due to retrotranslocation from the 
endoplasmic reticulum (or escape before translocation) or transmembrane anchoring, 
respectively (for review 
37
). In physiological conditions, these forms are rapidly cleared by 
quality control processes (ERAD (Endoplasmic-reticulum-associated protein degradation), 
aggresomes). However, in the prion disease state, or with mutated PrP mimicking familial forms 
of prion diseases, the levels of cytosolic PrP are increased 
37, 38
. The exact contribution of these 
variants to prion pathology remains unknown. PrP
C
 is also involved in many cellular processes 
and signaling pathways. These processes include response to oxidative stress, ER stress, 
apoptosis, proliferation and differentiation (reviewed in 
39--41
). Certain stress can even trigger 
unusual localization of PrP
C
 into the nucleus 
42
. Late stages of prion pathogenesis involve over-
activation of the PERK (protein kinase RNA-like endoplasmic reticulum kinase) pathway of the 
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unfolded protein response in experimental mouse models 
43
. Such pathways and the deregulation 
of the PrP-dependent physiological pathways, or a yet to discover PFAR-dependent proteostatic 
pathway in mammals 
44
, provide plenty of scope for direct or indirect interactions with PFAR to 
occur. 
PFAR involvement goes most probably further than prion-based diseases such as Creutzfeldt-
Jacob disease. There is indeed growing evidence that amyloid-based diseases like OPMD 
(Oculopharyngeal muscular dystrophy), Alzheimer’s, Parkinson’s and Huntington’s diseases 
share key biophysical and biochemical characteristics with prionopathies: they involve 
accumulation of aggregates of misfolded host-encoded proteins through prion-like processes of 
seeded polymerisation 
45--47
. As metazoa have no Hsp104p ortholog, the protein folding activity 
of domain V of the ribosome might thus correspond to the Hsp104-like activity responsible for 
amyloid handling that is absent in these organisms. This original hypothesis makes sense in light 
of our recent findings that some anti-prion compounds with anti-PFAR activity, like 6AP, GA 
and IQ, are also active in models of other protein aggregation-based diseases like Huntington’s 
disease, Parkinson’s disease (unpublished data) and OPMD 
48
. Our data thus indicate that PFAR 
involvement in amyloid handling may be shared by several human protein misfolding-based 
diseases, hence making PFAR a potential therapeutic target for human protein misfolding 
diseases. Despite the central role of PFAR in the proteostasis of the cell, it is still a promising 
therapeutic target to treat this class of diseases, either as a sole target or as part of a collaborative 
strategy targeting more than one cellular chaperone system. Indeed, its mild inhibition, together 
with other therapeutics, may help overcome the progression of these invariably fatal pathologies. 
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Figure 1. The sites of major importance for PFAR activity are included within the PTC 
region. The ribosomal large subunit is shown in light grey (Protein Data Bank code 4V6F). The 
yellow and blue helices indicate the two helices part of the symmetrical region forming the PTC 
cavity. The nucleotides involved in PFAR activity are numbered and represented as spheres 
(Thermus thermophilus numbering). The core of the PTC is indicated by a red sphere (Adapted 
from 
9
). Yeast nucleotide U2892 
6
 corresponds to position 2492.  
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Figure 2. Interplay between protein folding activities of Hsp104p and ribosome in 
modulating [PSI
+
] propagation (adapted from 
6
). A - Hsp104p and PFAR both participate in 
[PSI
+
] propagation. B - [PSI
+
] propagation is affected by enrichment or inhibition of Hsp104p 
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and PFAR. C - Hsp104p and PFAR interplay results in the compensation of the increase of one 
by the reduction of the other, and vice versa. OE, overexpression. GuHCl, Hsp104p inhibitor 
guanidine hydrochloride. ltv1∆ and yar1∆, PFAR-enriched yeast strains deleted for LTV1 or 
YAR1 genes 
6
. 
